Superior

Survival

Alecensa 1L has a >60% OS rate at 5 years1
the highest of any ALK+ therapy2

6 OUT OF 10 PATIENTS

WHO STARTED


ALECENSA 1L


ARE STILL


ALIVE


AFTER 5 YEARS1


Alecensa has demonstrated consistent survival
benefits across three phase III clinical trials1,3–6

J-ALEX

Phase III study in ALK-

inhibitor-naïve Japanese

patients with
ALK+ NSCLC1–4
(N=207)

Median PFS:3

ALECENSA: 34.1 months (95% CI: 22.1 NE)

Crizotinib: 10.2 months (95% CI: 8.3, 12.0)

HR=0.37 (95% CI: 0.26, 0.52)

5-year OS rate:4*

ALECENSA: 60.9% (95% CI: 51.4, 70.3)

Crizotinib: 64.1% (95% CI: 54.9, 73.4)

ALEX

Pivotal global Phase III

study in treatment-naïve

patients with
ALK+ NSCLC1,7,8
(N=303)

Median PFS:8

ALECENSA: 34.8 months (95% CI: 17.7, NE)

Crizotinib: 10.9 months (95% CI: 9.1, 12.9)

HR=0.43 (95% CI: 0.32, 0.58)

5-year OS rate:1

ALECENSA: 62.5% (95% CI: 54.3, 70.8)

Crizotinib: 45.5% (95% CI: 33.6, 57.4)

ALESIA

Phase III study in

treatment-naïve Asian

patients 

with ALK+ NSCLC9,10

(N=187)

Median PFS:9

ALECENSA: 41.6 months (95% CI: 33.1, 58.9)

Crizotinib: 11.1 months (95% CI: 9.1, 18.4)

HR=0.33 (95% CI: 0.23-0.49)

5-year OS rate:9

ALECENSA: 66.4% (95% CI: 57.9, 74.9)

Crizotinib: 56.0% (95% CI: 43.0, 69.1)

Discover

 

alecensa provides a

reassuring experience >

*No improvement in 5-year OS rates were observed in the J-ALEX study, likely confounded by treatment crossover which was permitted after study drug discontinuation.4

 

1L: first line; ALK: anaplastic lymphoma kinase; CI: confidence interval; HR: hazard ratio; ITT: intention-to-treat; mOS: median overall survival; NE, not estimable; NR: not reached; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; SmPC: Summary of Product Characteristics.

 

1. Mok T, et al. Ann Oncol 2020;31(8):1056–1064; 2. Ma H, et al. BMC Cancer 2021;21(1):1278; 3. Nakagawa K, et al. Lung Cancer 2020;139:195–199; 4. Hotta K, et al. ESMO Open 2022;7(4):100527; 5. Hida T, et al. Lancet 2017;390(10089):29–39; 6. Nishio M, et al. Lung Cancer 2018;121:37–40; 7. Peters S, et al. N Engl J Med 2017;377(9):829–838; 8. Camidge DR, et al. J Thorac Oncol 2019;14(7):1233–1243; 9. Zhou C, et al. Presented at the European Society for Medical Oncology Asia Congress (Abs. LBA11), 2–4 December 2022, Singapore; 10. Zhou C, et al. Lancet Respir Med 2019;7(5):437–446.